A092730 Stock Overview
NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
NeoPharm CO., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩25,550.00 |
| 52 Week High | ₩29,450.00 |
| 52 Week Low | ₩19,660.00 |
| Beta | 0.69 |
| 1 Month Change | 11.09% |
| 3 Month Change | -3.95% |
| 1 Year Change | 15.61% |
| 3 Year Change | -23.50% |
| 5 Year Change | -49.70% |
| Change since IPO | 207.55% |
Recent News & Updates
Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24
NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Recent updates
Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Shareholder Returns
| A092730 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -2.3% | 2.1% | 1.0% |
| 1Y | 15.6% | 13.0% | 8.7% |
Return vs Industry: A092730 exceeded the KR Personal Products industry which returned 10.1% over the past year.
Return vs Market: A092730 exceeded the KR Market which returned 9.5% over the past year.
Price Volatility
| A092730 volatility | |
|---|---|
| A092730 Average Weekly Movement | 4.5% |
| Personal Products Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A092730 has not had significant price volatility in the past 3 months.
Volatility Over Time: A092730's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 142 | Byeong-Deog Park | www.neopharm.co.kr |
NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand.
NeoPharm CO., LTD. Fundamentals Summary
| A092730 fundamental statistics | |
|---|---|
| Market cap | ₩199.82b |
| Earnings (TTM) | ₩23.21b |
| Revenue (TTM) | ₩97.10b |
8.6x
P/E Ratio2.1x
P/S RatioIs A092730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A092730 income statement (TTM) | |
|---|---|
| Revenue | ₩97.10b |
| Cost of Revenue | ₩31.72b |
| Gross Profit | ₩65.39b |
| Other Expenses | ₩42.17b |
| Earnings | ₩23.21b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.97k |
| Gross Margin | 67.33% |
| Net Profit Margin | 23.90% |
| Debt/Equity Ratio | 0.01% |
How did A092730 perform over the long term?
See historical performance and comparison